Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
about
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNSGSK-3β: A Bifunctional Role in Cell Death PathwaysGlycogen synthase kinase 3: more than a namesakeProtein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity.Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factorsGSK-3: tricks of the trade for a multi-tasking kinaseAntimicrobial, antimycobacterial and antibiofilm properties of Couroupita guianensis Aubl. fruit extractLithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptorGlycogen synthase kinase-3 regulates IGFBP-1 gene transcription through the thymine-rich insulin response elementMultiple phosphorylation events control mitotic degradation of the muscle transcription factor Myf5.Indirubin and Indirubin Derivatives for Counteracting Proliferative DiseasesAre the Traditional Medical Uses of Muricidae Molluscs Substantiated by Their Pharmacological Properties and Bioactive Compounds?Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsAn indirubin derivative, indirubin-3'-monoxime suppresses oral cancer tumorigenesis through the downregulation of survivinStructural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418Structural insight into the altered substrate specificity of human cytochrome P450 2A6 mutantsNeuroprotective Mechanisms Mediated by CDK5 InhibitionAdaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous systemDelayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke modelsTrypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leadsActivation of PP2A-like phosphatase and modulation of tau phosphorylation accompany stress-induced apoptosis in cultured oligodendrocytesGlycogen synthase kinase 3beta-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signalingThe specificities of protein kinase inhibitors: an updateComprehensive structural and functional characterization of the human kinome by protein structure modeling and ligand virtual screening.Identification of CLK1 Inhibitors by a Fragment-linking Based Virtual Screening.Chemical modulation of memory formation in larval zebrafish.Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.Catalyst-free synthesis of quinazolin-4-ones from (hetero)aryl-guanidines: application to the synthesis of pyrazolo[4,3-f]quinazolin-9-ones, a new family of DYRK1A inhibitors.p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.Cytochrome P450 enzymes in the generation of commercial products.Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity.Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylationCancer and virus leads by HTS, chemical design and SEA data miningDesigning of dual inhibitors for GSK-3β and CDK5: Virtual screening and in vitro biological activities studyAnti-Inflammatory Activity and Structure-Activity Relationships of Brominated Indoles from a Marine Mollusc.Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells.Structural basis for the modulation of CDK-dependent/independent activity of cyclin D1.Structure-based virtual screening of glycogen synthase kinase 3β inhibitors: analysis of scoring functions applied to large true actives and decoy sets.Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3 beta but not of cyclin-dependent kinase 5 and c-Jun NH2-terminal kinase and concomitantly abolishes hyperphosphorylation of tau: implications for Alzheimer's dNatural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1)
P2860
Q21129334-609A1DDD-DF55-44B1-90A7-9E397EDBBCEEQ21285144-D7E30A74-5597-4C7E-899B-C7620D4E31D9Q24315635-AF24D644-D87B-4637-86DD-63219CF4638BQ24317775-A33640D4-6F53-44EA-9EB1-68CBA647070BQ24562983-382E7176-3E31-4CC1-9F66-E8A1D2A6E793Q24624069-43043BB8-0A5D-4507-B4CF-080FBBAE6012Q24633975-79B102EC-7C77-4585-BAD3-F150569C19C1Q24791054-4337613C-344D-4FDC-9E4E-5B6A824D0B50Q24793511-AC788951-A07E-409D-ADE9-B443F08552B1Q24814111-59C25BC7-5C8F-4819-8D28-288FE29AFDE6Q26784341-D28E405E-AE7D-4CC1-93AC-4D423B9E5867Q26795884-19E33DF4-8DDF-4259-B5E5-D90C673BFBFDQ26827580-B55BD592-C837-4672-B077-A43FCFFFDE46Q27310385-21EF539C-8446-4515-AEBB-E208F4ACBF85Q27641873-9744E0A7-F2E0-4042-B78D-6275A77DD1ADQ27645089-9D8554B1-61C1-41B5-B96F-23B25CA63733Q28082792-FD8D243E-20B7-44AC-9A12-C2E2D92B7BC0Q28389419-4FA6328D-A8C8-4D83-9249-32A71A18A1CDQ28475093-A627B02E-D158-4A92-9B8D-FE5E9B8CF2A1Q28477646-B725D30C-7EA1-4F25-8ADD-30F9B47002C9Q28578658-0E95833C-E2B0-4790-82C3-984FBD630BF7Q28581844-0EC16B58-4499-4803-AD1E-F8298C29B656Q30014834-C3114485-4EC8-4DD2-90CD-FF3A352826E5Q30393891-93B7E3F7-1296-44B7-AFD1-4DD80295AB9AQ30396689-71D3F708-A851-434D-A126-A303EC5D8433Q30474076-6147EFA8-7CFC-4738-A1A6-D4C20B14F1FBQ30474415-9680C680-E750-4A30-B54E-7DE2234EF139Q30568278-8E34C815-AE49-4868-8016-CCE843D1E4CCQ30847612-4E3816C1-242A-4036-943A-4E3B33418B75Q31096798-9A5BED3F-0B1F-4BB7-92A7-050B786368AFQ31098941-8267D40D-610B-4D69-AC7D-BA0CBFC61DDDQ33300947-A18CA26E-0239-4915-AA39-743E12878DF2Q33508912-A9B35553-5A7E-4293-80E1-3D844D3E55FBQ33566835-BC76C8A7-A879-4921-A729-733AEAF839F1Q33744128-12E2E900-E045-4D32-BFEF-149876FB4828Q33770989-BB272B9D-2AD1-4287-823D-05C1F72EC200Q33829852-57D4071F-07A0-4C16-91E1-1E72A011AFB6Q33934472-B0363D38-E288-42C1-868C-0220729F16A0Q34008372-7E23324C-E28E-4FD2-BFEA-66DD6DBC2A57Q34009713-183F260F-08F0-4784-9B6F-9B3459F5210D
P2860
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Indirubins inhibit glycogen sy ...... n-dependent kinase inhibitors?
@en
Indirubins inhibit glycogen sy ...... n-dependent kinase inhibitors?
@nl
type
label
Indirubins inhibit glycogen sy ...... n-dependent kinase inhibitors?
@en
Indirubins inhibit glycogen sy ...... n-dependent kinase inhibitors?
@nl
prefLabel
Indirubins inhibit glycogen sy ...... n-dependent kinase inhibitors?
@en
Indirubins inhibit glycogen sy ...... n-dependent kinase inhibitors?
@nl
P2093
P50
P356
P1476
Indirubins inhibit glycogen sy ...... n-dependent kinase inhibitors?
@en
P2093
G Eisenbrand
G L Snyder
P304
P356
10.1074/JBC.M002466200
P407
P577
2001-01-01T00:00:00Z